NCT03386513
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 32 versions: 30 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 6 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Trial completed
- Trial sites reduced: 29 → 18 locations
- Study completion date changed from estimate of Dec 30, 2026 to Oct 1, 2026
- Secondary endpoints: details revised at 18 of 23 entries
- Publications: details revised at 2 of 2 entries
- Notable Primary completion pushed from Sep 6, 2023 to Oct 2, 2024
- Primary endpoint(s) modified
- Results posted: Sep 4, 2026
- Notable Primary completion date: Sep 6, 2023 to Oct 2, 2024
- Primary endpoint revised
- Study sites: 28 to 29
- Secondary endpoints: 11 to 23
- Minor Study completion date: Dec 1, 2025 to Dec 30, 2026v29
- Notable Lead sponsor: ImmunoGen, Inc. to AbbViev28
Show 24 earlier versionsHide 24 earlier versions
- Minor Primary completion date changed from estimate of Dec 2024 to Sep 6, 2023
- Study completion date: Dec 2025 to Dec 1, 2025
Notable Eligibility criteria expanded, about 67 wordsv26 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 252 to confirmed 179
- Study sites: 27 to 28
- Study description shortened, about 33 words
- Notable Eligibility criteria expanded, about 24 words
- Study sites: 24 to 27
- Minor Study sites: 23 to 24v24
- Notable Primary completion date: Jun 2022 to Dec 2024
- Eligibility criteria shortened, about 76 words
- Study sites: 15 to 23
- Study completion date: Dec 2022 to Dec 2025
- Minor Site details revised at 3 of 15 sitesv22
- Minor Site details revised at 1 of 15 sitesv21
- Minor Site details revised at 1 of 15 sitesv20
- Minor Study sites revised (15)
- Study title shortened, about 3 words
Notable Primary completion date: Aug 2020 to Jun 2022v17 Show 8 more changesShow less
- Eligibility criteria expanded, about 8 words
- Primary endpoint revised
- Enrollment target: 212 to 252
- Study sites: 12 to 15
- Study completion date: Feb 2021 to Dec 2022
- Secondary endpoints: 6 to 11
- Study description shortened, about 13 words
- Collaborators shortened, about 2 words
- Notable Phase: Phase 1 to Phase 1/2
- Eligibility criteria expanded, about 94 words
- Enrollment target: 155 to 212
- Study sites: 11 to 12
- Minor Site contacts updated at 5 of 11 sitesv15
- Notable Eligibility criteria expanded, about 26 words
- Start date: Jan 4, 2018 to Jan 2, 2018
- Minor Study sites: 7 to 11v13
- Minor Study sites: 6 to 7v12
- Minor Study sites: 5 to 6v10
- Minor Study sites: 4 to 5v9
- Minor Site contacts updated at 1 of 4 sitesv8
- Notable Eligibility criteria revisedv7
- Minor Study sites: 3 to 4v6
- Minor Study sites: 1 to 3v5
- Minor Site contact updatedv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2018 to Jan 4, 2018
- Site details revised
- Minor Start date: Dec 2017 to Jan 2018v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (23)
Show 18 moreShow less
Arms and interventions
Escalation: IMGN632 was administered by IV on 2 different schedules for participants with relapsed/refractory AML, ALL, or BPDCN. Expansion: IMGN632 was administered by IV: * Cohort 1: Relapsed or refractory BPDCN participants who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN) * Cohort 2: Relapsed AML * Cohort 3: Relapsed or refractory ALL * Cohort 4: Other relapsed or refractory hematologic malignancies * Cohort 5: Relapsed or refractory AML at alternate dose or schedule * Cohort 6: Pivotal cohort for frontline BPDCN participants who have not received prior systemic therapy and participants with frontline BPDCN who have prior or concomitant hematologic malignancy (PCHM) and have not received prior systemic therapy.
Drugs: IMGN632
Sites
18 sites in 4 countries
United States 11, France 4, Italy 2, Spain 1